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Multiple sodium channel isoforms 
mediate the pathological effects of 
Pacific ciguatoxin-1
Marco C. Inserra1,*, Mathilde R. Israel1,*, Ashlee Caldwell2,3,*, Joel Castro2,3,*, 
Jennifer R. Deuis1,*, Andrea M. Harrington2,3, Angelo Keramidas4, Sonia Garcia-
Caraballo2,3, Jessica Maddern2,3, Andelain Erickson2,3, Luke Grundy2,3, Grigori Y. Rychkov3, 
Katharina Zimmermann5, Richard J. Lewis1, Stuart M. Brierley2,3 & Irina Vetter1,6
Human intoxication with the seafood poison ciguatoxin, a dinoflagellate polyether that activates 
voltage-gated sodium channels (NaV), causes ciguatera, a disease characterised by gastrointestinal and 
neurological disturbances. We assessed the activity of the most potent congener, Pacific ciguatoxin-1 
(P-CTX-1), on NaV1.1–1.9 using imaging and electrophysiological approaches. Although P-CTX-1 
is essentially a non-selective NaV toxin and shifted the voltage-dependence of activation to more 
hyperpolarising potentials at all NaV subtypes, an increase in the inactivation time constant was 
observed only at NaV1.8, while the slope factor of the conductance-voltage curves was significantly 
increased for NaV1.7 and peak current was significantly increased for NaV1.6. Accordingly, P-CTX-1-
induced visceral and cutaneous pain behaviours were significantly decreased after pharmacological 
inhibition of NaV1.8 and the tetrodotoxin-sensitive isoforms NaV1.7 and NaV1.6, respectively. The 
contribution of these isoforms to excitability of peripheral C- and A-fibre sensory neurons, confirmed 
using murine skin and visceral single-fibre recordings, reflects the expression pattern of NaV isoforms 
in peripheral sensory neurons and their contribution to membrane depolarisation, action potential 
initiation and propagation.
Ciguatera is the most common non-bacterial form of fish-borne illness and is caused by the consumption of fish 
contaminated with ciguatoxins1. These polycyclic ethers are lipophilic, heat stable ichthyotoxins that originate 
from benthic dinoflagellates of the genus Gambierdiscus that bloom in tropical and sub-tropical oceans around 
the world. Consumption of coral and seaweed contaminated with Gambierdiscus by herbivorous fish leads to 
bioaccumulation of the ciguatoxins through the food chain via larger carnivorous fish that in turn are consumed 
by humans and cause ciguatera. The communities most affected by ciguatera are those that rely on fish as a major 
part of their diet such as the island nations of the Pacific and Indian Oceans and the Caribbean Sea2–4. However, 
as the world’s oceans warm and algal blooms become more frequent, ciguatera is now emerging as a significant 
issue in Asia, America and parts of Europe5–8.
The presenting symptoms of ciguatera are predominantly neurotoxic in the majority of cases and include 
post-ingestion paraesthesiae, dysaesthesiae and heightened nociception, including the pathognomonic symp-
tom of cold allodynia, which is associated with intense discomfort on exposure to cool temperatures1,9–11. In 
addition, early signs of ciguatera include gastrointestinal symptoms such as diarrhoea, vomiting and abdominal 
pain as well as musculoskeletal symptoms, in particular weakness and fatigue1. Cardiovascular symptoms such 
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as bradycardia occur more rarely and often in more severe cases of poisoning12–15. This diverse symptomatology 
is believed to be caused by the interaction of the ciguatoxins with site 5 of the voltage-gated sodium channels 
(NaV)11,16–18. Mammalian NaV channels NaV1.1–1.9 comprise a voltage-sensitive pore-forming α -subunit, which 
may also be associated with one of four auxiliary β -subunits that can modify the gating and kinetic profile of 
the α -subunit. The α -subunit consists of four homologous domains each containing six transmembrane seg-
ments that form the pore and facilitate voltage-sensing and ligand binding. Pacific ciguatoxin-1 (P-CTX-1), the 
most potent ciguatoxin congener thought to be responsible for the majority of symptoms associated with cigu-
atera in the Pacific19, elicits varied effects on the electrophysiological properties of NaV channels and as a con-
sequence enhances neuronal excitability. In dorsal root ganglion (DRG) neurons, P-CTX-1 shifts the voltage of 
activation of tetrodotoxin-sensitive (TTX-s) NaV channels to more hyperpolarised potentials and decreases peak 
tetrodotoxin-resistant (TTX-r) Na+ current20. Similarly, in parasympathetic neurons P-CTX-1 enhances the open 
probability of single TTX-sensitive NaV channels without altering the unitary conductance or reversal potential21. 
However, while it is known that the ciguatoxins modulate activity of TTX-s and TTX-r NaV isoforms, the relative 
selectivity for and pharmacological effects on individual NaV isoforms, and their association with diverse patho-
physiological consequences have not been assessed to-date. Thus, the aims of the present study were to determine 
the relative activity and subtype-selectivity of the most potent congener of the ciguatoxins, P-CTX-1, on the 
mammalian NaV isoforms NaV1.1–1.9 and to define the NaV isoforms that contribute to the in vivo symptomatol-
ogy associated with ciguatera.
Results
Subtype-selectivity of P-CTX-1 at NaV1.1–1.9. Although ciguatoxin is known to affect TTX-sensitive 
and TTX-resistant NaV channels20, the specific effects of P-CTX-1 on individual NaV subtypes have not previ-
ously been reported. We first assessed the relative potency and selectivity of P-CTX-1 for NaV isoforms using 
a high-throughput membrane potential assay22. In HEK293 cells stably expressing hNaV1.1–1.8, P-CTX-1 elic-
ited a concentration-dependent potentiation of NaV-mediated responses with little subtype-selectivity (Fig. 1a; 
EC50 ± SEM: NaV1.1, 7.9 ± 3.1 nM; NaV1.2, 8.3 ± 3.9 nM; NaV1.3, 3.4 ± 1.6 nM; NaV1.4, 18.4 ± 6.9 nM; NaV1.5, 
10.8 ± 3.8 nM; NaV1.6, 18.1 ± 9.4 nM; NaV1.7, 13.0 ± 5.8 nM; NaV1.8, 2.1 ± 0.7 nM). Overall, NaV1.3 and NaV1.8 
were most potently affected, while NaV1.4 was the isoform least potently affected, although the relative selectiv-
ity for these isoforms was not statistically significant (ANOVA, p > 0.05). These results indicate that P-CTX-1 
is a potent but relatively non-specific modulator of NaV channels. Therefore, we sought to assess the effects of 
P-CTX-1 on the electrophysiological properties of hNaV1.1–1.9 in more detail.
Differential effects of P-CTX-1 on the electrophysiological parameters of NaV1.1–1.9. Using 
whole cell patch-clamp recordings, we further assessed the effects of P-CTX-1 on the electrophysiological param-
eters of hNav1.1–1.9 expressed heterologously in HEK293 cells (Figs 1b and 2 and Table 1). The effect of P-CTX-1 
on peak current was voltage-dependent, causing an increase in peak current at more hyperpolarised potentials at 
all subtypes (Fig. 2), with maximal peak current significantly increased only for NaV1.6 (Table 1). Accompanying 
the voltage-dependent changes in peak current, P-CTX-1 significantly shifted the V1/2 for the voltage-dependence 
of activation to more hyperpolarising potentials at all NaV subtypes (Δ V1/2 activation: NaV1.1, − 5.1 mV; NaV1.2, 
− 6.3 mV; NaV1.3, − 5.0 mV; NaV1.4, − 3.4 mV; NaV1.5, − 6.1 mV; NaV1.6, − 3.4 mV; NaV1.7, − 5.7 mV; NaV1.8, 
− 11.3 mV; NaV1.9, − 8.9 mV; Figs 1b and 2 and Table 1). These effects are consistent with NaV channel activa-
tor activity and were not observed in time-matched controls. Interestingly, P-CTX-1 also significantly changed 
the slope factor of the conductance-voltage curves for NaV1.3, NaV1.6, NaV1.7 and NaV1.8 (Fig. 2 and Table 1). 
Figure 1. P-CTX-1 subtype selectivity assessed using a high-throughput membrane potential FLIPRTetra 
assay. (a) P-CTX-1 concentration-dependently potentiated veratridine-induced responses in mammalian cells 
heterologously expressing NaV1.1–NaV1.8 with little subtype selectivity. (b) P-CTX-1 (10 nM) induced shifts in 
the voltage of activation at NaV1.1–NaV1.8 and the voltage-dependence of inactivation at NaV1.2, NaV1.3 and 
NaV1.4. Data are presented as mean ± SEM from n = 3–6 independent experiments.
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For NaV1.3, NaV1.6 and NaV1.8, the slope factor decreased, indicating higher conductance at more depolarised 
membrane potentials, whilst for NaV1.7 the slope factor increased, indicating higher conductance at more hyper-
polarised membrane potentials.
Figure 2. Effects of P-CTX-1 on the electrophysiological parameters of NaV1.1–1.9 assessed by automated 
whole-cell patch clamping in mammalian cells. P-CTX-1 (white triangles) caused a leftward shift in the I-V 
curves at all NaV subtypes compared to control (black triangles). P-CTX-1 (white circles) significantly shifted 
the V1/2 of voltage-dependence of activation to more hyperpolarised potentials at all NaV subtypes compared to 
control (black circles). P-CTX-1 (white squares) only caused a significant shift in the V1/2 of voltage-dependence 
of steady-state fast inactivation at NaV1.2, NaV1.3, NaV1.4 and NaV1.9 compared to control (black squares). 
Imax is the maximal peak amplitude, determined for each cell, in the absence of the toxin. Data are presented as 





V1/2 (mV) k (mV) V1/2 (mV) k (mV)
NaV1.1
— 0.99 ± 0.00 − 20.2 ± 0.4 4.5 ± 0.3 − 51.8 ± 1.2 − 6.7 ± 1.1
+ 0.95 ± 0.04 − 25.3 ± 0.7* 4.7 ± 0.6 − 53.8 ± 1.3 − 6.9 ± 1.2
NaV1.2
— 1.00 ± 0.00 − 20.6 ± 0.3 4.4 ± 0.3 − 53.4 ± 0.6 − 4.1 ± 0.5
+ 0.86 ± 0.09 − 26.9 ± 0.8* 4.9 ± 0.7 − 60.3 ± 1.2* − 5.6 ± 1.1*
NaV1.3
— 1.00 ± 0.00 − 19.7 ± 0.3 4.9 ± 0.2 − 58.0 ± 0.5 − 4.1 ± 0.5
+ 1.08 ± 0.04 − 24.7 ± 0.3* 3.9 ± 0.2* − 60.1 ± 0.6* − 4.2 ± 0.7
NaV1.4
— 0.93 ± 0.04 − 36.8 ± 0.4 1.8 ± 0.3 − 63.8 ± 0.5 − 4.6 ± 0.4
+ 0.74 ± 0.16 − 40.2 ± 0.8* 2.8 ± 0.7 − 57.3 ± 1.5* − 5.8 ± 1.4
NaV1.5
— 0.93 ± 0.03 − 37.6 ± 1.0 4.6 ± 0.9 − 72.3 ± 0.6 − 5.8 ± 0.6
+ 0.85 ± 0.07 − 43.7 ± 1.3* 4.8 ± 1.1 − 72.8 ± 0.8 − 6.2 ± 0.7
NaV1.6
— 1.00 ± 0.00 − 19.2 ± 0.2 4.8 ± 0.2 − 56.0 ± 0.4 − 5.1 ± 0.3
+ 1.11 ± 0.03* − 22.6 ± 0.2* 3.5 ± 0.2* − 57.1 ± 0.9 − 5.4 ± 0.8
NaV1.7
— 0.91 ± 0.02 − 33.2 ± 0.6 3.2 ± 0.5 − 62.4 ± 0.4 − 4.4 ± 0.4
+ 0.74 ± 0.10 − 38.9 ± 1.5* 6.4 ± 1.4* − 64.4 ± 0.9 − 5.7 ± 0.8
NaV1.8
— 0.94 ± 0.02 − 5.6 ± 0.6 7.7 ± 0.6 − 35.3 ± 1.7 − 8.7 ± 1.5
+ 1.00 ± 0.08 − 16.9 ± 0.3* 4.0 ± 0.2* − 36.1 ± 1.7 − 7.9 ± 1.5
NaV1.9
— 0.99 ± 0.01 − 48.3 ± 0.7 7.8 ± 0.6 − 31.1 ± 2.1 − 11.4 ± 1.6
+ 1.06 ± 0.15 − 57.2 ± 1.1* 8.4 ± 1.0 − 41.7 ± 2.6* − 12.7 ± 2.2
Table 1.  Effects of P-CTX-1 on NaV channel voltage dependence of activation and steady-state fast 
inactivation.  Electrophysiological parameters at hNaV1.1–hNaV1.9 heterologously expressed in HEK293 cells 
were assessed using whole-cell voltage-clamp recordings. Data are reported as mean ± SEM from 4–10 cells. 
*Indicates P < 0.05 compared to control.
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The effects of P-CTX-1 on the voltage-dependence of steady-state fast inactivation were less profound. A 
significant hyperpolarising shift was observed in the V1/2 for NaV1.2, NaV1.3 and NaV1.9, with a significant 
depolarising shift occurring only at NaV1.4 (Δ V1/2 inactivation: NaV1.1, − 2.0 mV; NaV1.2, − 6.9 mV; NaV1.3, 
− 2.1 mV; NaV1.4, + 6.5 mV; NaV1.5, − 0.5 mV; NaV1.6, − 1.1 mV; NaV1.7, − 2.0 mV; NaV1.8, − 0.8 mV; NaV1.9, 
− 10.6 mV; Fig. 2 and Table 1). P-CTX-1 had differential effects on NaV channel activation and inactivation kinet-
ics, including significantly decreasing the time to peak at NaV1.2, significantly decreasing the inactivation time 
constant for NaV1.1, NaV1.2 and NaV1.3, and increasing the inactivation time constant for NaV1.8 (Fig. 3 and 
Table 2). P-CTX-1 also produced a significant persistent current at NaV1.3 (I/Imax, 3.4 ± 0.8%) and NaV1.8 (I/Imax, 
7.6 ± 0.2%).
P-CTX-1 reduces the activation threshold of single NaV1.8 and NaV1.7 channels and length-
ens their active periods. Our whole-cell measurements indicated that P-CTX-1 lowers the threshold for 
activation of NaV1.7 and NaV1.8, two key isoforms contributing to action potential generation and propagation 
in nociceptive neurons (Fig. 2, Table 1). However, in the presence of P-CTX-1, currents mediated by NaV1.8 
channels inactivated with a slower time constant than those mediated by NaV1.7 (Fig. 3, Table 2). We thus used 
single channel recordings to further investigate how P-CTX-1 potentiated NaV1.7 and NaV1.8 by measuring single 
channel current amplitude and the duration of single channel active periods (activations).
Excised outside-out membrane patches expressing NaV1.8 channels were subjected to an activating voltage 
step of − 100 mV to − 20 mV (Fig. 4). At − 100 mV, channel activations were too infrequent for any reliable anal-
ysis (Fig. 4a). However, depolarising the patch to − 20 mV elicited brief bursts of single NaV1.8 channel open-
ings. Multiple amplitude levels were discernible at − 20 mV, the predominant ones being a large (1.36 ± 0.03 pA; 
duration 0.8 ± 0.2 ms) and a small (0.63 ± 0.04 pA; duration 10.5 ± 1.0 ms) amplitude opening. After exposure 
to P-CTX-1 (1 nM), significant channel activity at both amplitude levels was observed at − 100 mV and − 20 mV 
(Fig. 4b). The two amplitudes were slightly larger at − 100 mV (1.64 ± 0.08 and 0.69 ± 0.05 pA) than at − 20 mV 
(1.43 ± 0.04 pA and 0.63 ± 0.02 pA), reflecting the difference in driving force (in the absence of Na+ in the pipette 
solution), but were essentially unchanged in the presence of P-CTX-1. However, P-CTX-1 did produce dramatic 
effects on the duration of single channel activations (Fig. 4b and c). At − 100 mV, the mean duration of the large 
channel activations was substantially longer (1357 ± 122 ms) than at − 20 mV (3.6 ± 0.8 ms), lasting over 5 s in 
some patches (Fig. 4c). Conversely, the duration of the smaller amplitude activations were enhanced more at 
− 20 mV (1821 ± 138 ms) than at − 100 mV (165 ± 14 ms; Fig. 4d).
The above experiments were repeated on excised membrane patches expressing NaV1.7 channels. At − 100 mV, 
NaV1.7 channels were mostly inactive, whereas stepping the membrane potential to − 20 mV elicited short-lived 
channel openings (Fig. 4e) of similar amplitude to those mediated by NaV1.8 channels. Again, two main ampli-
tudes were discernible. The larger amplitude was predominant (> 90% of openings, amplitude 1.28 ± 0.03 pA, 
Figure 3. Representative effects of P-CTX-1 on NaV1.1–1.8 currents assessed by automated whole-cell 
patch clamping in mammalian cells. Currents were elicited using a holding potential of − 80 mV, followed by 
a pre-pulse of − 100 mV for 50 ms and then a 50 ms pulse of − 20 mV for NaV1.1–1.7 and + 10 mV for NaV1.8. 
Black traces represent control current and grey traces represent current in the presence of P-CTX-1.
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duration 3.1 ± 0.2 ms), whereas the smaller amplitude openings were rarely observed (< 10% of openings, ampli-
tude 0.74 ± 0.03 pA, duration 1.6 ± 0.1 ms). After exposure of the recorded patches to P-CTX-1, significant 
activity was observed at − 100 mV (Fig. 4f and g), however, at − 20 mV the frequency of openings was markedly 
reduced compared with control (Fig. 4f). As for the NaV1.8 channels, both the larger and smaller NaV1.7 ampli-
tude openings were relatively unaffected by P-CTX-1 at either − 100 mV (larger amplitude, 1.67 ± 0.03 pA; smaller 
amplitude, 0.87 ± 0.03 pA) or − 20 mV (larger amplitude, 1.31 ± 0.04 pA; smaller amplitude 0.75 ± 0.03 pA). In 
contrast to NaV1.8, P-CTX-1 had relatively minor effects on the mean durations of NaV1.7 single channel activity, 
which were increased for larger (5.3 ± 0.9 ms mean duration) and smaller (9.5 ± 2.5 ms mean duration) ampli-
tudes at − 100 mV. At − 20 mV the mean durations for large and small amplitude openings were 3.3 ± 0.4 ms and 
3.6 ± 0.9 ms, respectively (Fig. 4h).
The single channel experiments confirmed that the effects of P-CTX-1 on NaV1.8 substantially differ from 
effects on NaV1.7. The most apparent common effect of P-CTX-1 on NaV1.7 and NaV1.8 was a decrease of the 
threshold of activation to a level where the channels are not normally active (− 100 mV). This effect also manifests 
in the whole-cell data, with a decrease in the V1/2 for activation for both subtypes (Table 1). Although P-CTX-1 
generally lengthened the periods of discrete single channels activations in both subtypes, the effect on NaV1.8 
was substantially greater. The P-CTX-1-induced increase in the duration of the activations likely underlies the 
significant increase in the inactivation time constant of ensemble currents (Table 2).
Contribution of NaV isoforms to P-CTX-1-induced responses of sensory dorsal root ganglion 
neurons. As individual sensory neurons can express multiple NaV isoforms, we next assessed the relative 
contribution of TTX-s and TTX-r NaV isoforms to P-CTX-1-induced responses using fluorescent live cell imag-
ing of cultured dorsal root ganglion (DRG) neurons. At a concentration of 5 nM, P-CTX-1 elicited Na+ influx in 
most DRG neurons, albeit the size of the responses varied considerably (Fig. 5a). Consistent with the observed 
effect on the electrophysiological properties of NaV1.8, P-CTX-induced Na+ influx was significantly decreased in 
DRG neurons from NaV1.8−/− animals (Control (Δ F), 1285 ± 15; NaV1.8−/− (Δ F), 1140 ± 8; p < 0.001, Fig. 5a). 
Nevertheless, many individual cells still responded with large increases in intracellular Na+ to application of 
P-CTX-1. Similarly, treatment of DRG neurons with TTX (1 μ M) significantly decreased P-CTX-1-induced 
responses compared with control, although several cells with large responses remained, supporting an impor-
tant contribution of both TTX-s and TTX-r isoforms to the enhanced sensory neuronal excitability induced 
by P-CTX-1 (Control (Δ F), 1285 ± 15; TTX (Δ F), 1138 ± 19; p < 0.001, Fig. 5a). Exposure of DRG neurons 
from NaV1.8−/− animals to TTX (1 μ M) further decreased responses (NaV1.8−/− + TTX (Δ F), 1050 ± 23, p < 0.01, 
Fig. 5a), although some small responses remained. Whilst overall, Na+ influx was not significantly changed in 
DRGs from NaV1.9−/− animals (NaV1.9−/− (Δ F), 1310 ± 25, p > 0.01, Fig. 5a), the presence of small P-CTX-
1-evoked responses in NaV1.8−/− DRG neurons treated with TTX indicates that NaV1.9 contributes to P-CTX-
1-induced Na+ influx in some cells (Fig. 5a).
As a secondary process to Na+ channel activation, we also assessed P-CTX-1 induced Ca2+ influx in DRG 
neurons. Similar to what we observed with Na+ entry, P-CTX-1 (1 nM) elicited Ca2+ influx in most DRG neurons 
with considerable variability in the size and magnitude of the responses (Fig. 5b). Treatment with TTX (1 μ M) sig-
nificantly decreased P-CTX-1-induced Ca2+ responses compared with control P-CTX-1 response (*p < 0.0001), 
although several large responses remained. This further supports an important contribution of both TTX-s and 
TTX-r isoforms to the enhanced sensory neuronal excitability induced by P-CTX-1.
P-CTX-1





— 1.23 ± 0.05 2.10 ± 0.26
+ 1.15 ± 0.10 1.20 ± 0.17*
NaV1.2
— 1.06 ± 0.05 1.45 ± 0.17
+ 0.78 ± 0.07* 0.79 ± 0.04*
NaV1.3
— 1.08 ± 0.09 0.89 ± 0.09
+ 1.05 ± 0.07 0.61 ± 0.05*
NaV1.4
— 0.69 ± 0.04 0.35 ± 0.04
+ 0.88 ± 0.11 0.46 ± 0.04
NaV1.5
— 0.86 ± 0.06 0.85 ± 0.11
+ 0.81 ± 0.07 1.00 ± 0.18
NaV1.6
— 1.03 ± 0.09 1.38 ± 0.22
+ 1.03 ± 0.08 1.09 ± 0.18
NaV1.7
— 1.09 ± 0.09 0.47 ± 0.04
+ 0.91 ± 0.06 0.49 ± 0.04
NaV1.8
— 1.06 ± 0.07 1.51 ± 0.21
+ 1.32 ± 0.10 3.06 ± 0.43*
Table 2.  Effects of P-CTX-1 on NaV channel activation and inactivation kinetics. Electrophysiological 
parameters at hNaV1.1-hNaV1.9 heterologously expressed in HEK293 cells were assessed using whole-cell 
voltage-clamp recordings. Data are reported as mean ± SEM from 4–10 cells. *Indicates P < 0.05 compared to 
control.
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Figure 4. Effect of P-CTX-1 on single channel activity of NaV1.7 and NaV1.8. (a) Single channel activity 
recorded from a membrane patch expressing Nav 1.8 channels after depolarising the membrane from − 100 mV 
to − 20 mV (shown above). Two main amplitudes were apparent, but only at − 20 mV. These are boxed in red 
and shown on an expanded time scale below. (b) A similar activation protocol was applied to a recorded patch 
after exposing it to 1 nM P-CTX-1 for 10 minutes. Note the presence of activity at − 100 mV and − 20 mV 
of both amplitude levels. Areas boxed in red are shown below on an expanded time scale. (c) Continuous 
recording from a patch exposed to 1 nM P-CTX-1 for 10–12 minutes at − 100 mV showing long activation 
periods, interrupted by brief inactivity, likely corresponding to channel inactivation. The two lower current 
traces are from the same patch but on an expanded time scale. (d) Summary plots of the mean durations of 
activations before (Ctrl) and after (P-CTX-1) exposure to P-CTX-1 for activations at both amplitude levels.  
(e) Single channel recordings from a patch expressing NaV 1.7 channels, showing negligible activity at − 100 mV, 
but significant activity at − 20 mV. The sections boxed in red are shown below at a higher temporal resolution.  
(f) After exposing the recorded path to 1 nM P-CTX-1 for 10 minutes the channels exhibited frequent openings 
at − 100 mV, but less activity at − 20 mV. Selected sections are boxed in red and shown at higher temporal 
resolution below. (g) Sample currents after exposure to P-CTX-1 at − 100 mV at two temporal resolutions 
(above) and control sweeps (black) and after P-CTX-1 exposure (green) at − 20 mV, showing a reduction in 
channel activity. (h) Summary plots of the mean durations of activations before (Ctrl) and after (P-CTX-1) 
exposure to P-CTX-1 for activations at both amplitude levels.
www.nature.com/scientificreports/
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As the early signs of ciguatera include gastrointestinal symptoms such as abdominal pain, we tested P-CTX-1 
on DRG neurons that specifically innervate the colon. We found that P-CTX-1-induced Ca2+ responses were 
qualitatively similar in colonic sensory neurons to those in non-colonic neurons (Fig. 5c), with 83.3% (15/18) 
of colonic DRG neurons activated by P-CTX-1. The size of the responses also varied considerably including 
small (46.8% of all activated neurons), medium (26.7% of all activated neurons) and large (26.7% of all acti-
vated neurons) magnitude responses (Fig. 5c). TTX (0.5 μ M) reduced the number of colonic DRG neurons acti-
vated by P-CTX-1 to 58.3% (7/12), and also reduced the magnitude of Ca2+ influx induced by P-CTX-1 (Fig. 5c). 
The P-CTX-1-induced large magnitude responses in colonic neurons appeared to be predominantly mediated 
by TTX-s channels (Fig. 5c), as only 5% (1 out of 18) of colonic DRG neurons responded to P-CTX-1 when 
co-incubated with TTX compared with 33% (4 out 12) of colonic DRG neurons with large responses induced by 
P-CTX-1 alone.
P-CTX-1 evokes action potential firing in dermal and colonic sensory afferents. To further phar-
macologically explore the contribution of individual NaV subtypes to enhanced excitability induced by P-CTX-1, 
we recorded propagated action potentials from single receptive fields of sensory afferents, recorded extracellularly 
from murine skin-saphenous nerves and from colonic splanchnic nerves.
In the murine skin-saphenous nerve preparation, P-CTX-1 (0.5 nM) induced action potential firing in all 
previously quiescent C fibres (12/12), with some fibres exhibiting a modest increase in activity (4/12 fibres; 
< 50 action potentials/5 min) (Fig. 6a). Consistent with our previous findings9, action potential firing induced by 
P-CTX-1 in the skin was mediated predominantly by TTX-r NaV isoforms in C-fibres, as treatment with the selec-
tive NaV1.7 inhibitor Pn3a23 (1 μ M, Suppl Fig. 1), the NaV1.6 inhibitor GIIIA (10 μ M), or TTX (1 μ M) did not sig-
nificantly decrease action potential firing overall (p > 0.05, Fig. 6a). However, some individual fibres (4/12) were 
silenced after inhibition of TTX-s NaV isoforms (Fig. 6b). Notably, the P-CTX-1-induced firing frequency of these 
fibres was modest (action potentials/5 min: 53.2 ± 40.6) in comparison with fibres that were unaffected by TTX 
(action potentials/5 min: 166.1 ± 66.6). Similar to our previous findings using recordings from NaV1.8−/− ani-
mals9, where P-CTX-1-induced firing in C-fibres was markedly decreased, the NaV1.8 inhibitor A803467 (10 μ M; 
p < 0.05) significantly decreased action potential firing frequency by 62.8 ± 15.5% (Fig. 6c).
In contrast, P-CTX-1 elicited action potential firing in only 44.8% (13/29) of A-fibres, with responding fibres 
displaying significantly (p < 0.05) slower conduction velocities (6.28 ± 0.95 m/s, n = 6) than non-responders 
(10.64 ± 1.50 m/s, n = 5). Inhibition of the TTX-s isoforms NaV1.6 or NaV1.7 had a profound effect on action 
potential firing in A-fibres, with both Pn3a and GIIIA almost completely silencing P-CTX-1-induced activ-
ity (Fig. 6d). Interestingly, inhibition of either NaV1.7 (Fig. 6e) or NaV1.6 (Fig. 6f) appeared to be sufficient to 
virtually abolish spontaneous action potential firing, suggesting that both channels act in concert to maintain 
Figure 5. P-CTX-1 induced responses in isolated dorsal root ganglion neurons. (a) Increases in intracellular 
Na+ in response to P-CTX-1 (1 nM) were assessed in dissociated DRG neurons from wild-type, NaV1.8−/− and 
NaV1.9−/− mice in the absence and presence of TTX (1 μ M). P-CTX-1-induced responses were significantly 
(*P < 0.0001) decreased in DRGs from NaV1.8−/−, but not NaV1.9 −/− mice and after treatment with TTX. Data 
is presented as mean ± SEM from n = 51–163 cells/group. (b) Increases in intracellular Ca2+ in response to 
P-CTX-1 (1 nM) were assessed in dissociated DRG neurons from wild-type mice in the absence and presence  
of TTX (1 μ M). P-CTX-1-induced responses were significantly decreased in DRG neurons co-incubated with 
TTX (*P < 0.0001). Data is presented as mean ± SEM from n = 49 neurons (P-CTX-1) and n = 57 neurons  
(P-CTX-1 + TTX). (c) P-CTX-induced activation of intracellular Ca2+ within identified colonic DRG neurons. 
Note that 1 nM P-CTX-1 induced a different magnitude of responses (small, medium and large). TTX (0.5 μ M) 
reduced P-CTX-1-induced activation of colonic DRG neurons. This reduction was specially marked in colonic 
neurons exhibiting large responses when co-incubated with TTX. Data is presented as mean ± SEM from n = 18 
colonic DRG neurons (P-CTX-1) and n = 12 colonic DRG neurons (P-CTX-1 + TTX). *P < 0.0001 using One-
way ANOVA (a) or student’s t-test (b,c).
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Figure 6. P-CTX-1 induces spontaneous action potential firing in peripheral sensory afferents. (a) Effect of 
P-CTX-1 (0.5 nM) on single C-fibres recorded from a skin-saphenous nerve preparation in the mouse. Selective 
inhibitors of NaV1.7 (Pn3a, 1 μ M); NaV1.6 (GIIIA, 10 μ M), TTX-s NaV isoforms (TTX, 1 μ M) and NaV1.8 
(A803467, 10 μ M) were sequentially perfused at the receptive field to assess cumulative effects of NaV inhibition 
on action potential firing. Each data point represents the number of action potentials/5 min from a single 
C-fibre receptive field. (b) Representative recording of a C-fibre silenced by the selective NaV1.7 inhibitor Pn3a 
www.nature.com/scientificreports/
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P-CTX-1-induced ongoing activity. Thus, both TTX-s and TTX-r isoforms contribute to the enhanced excitabil-
ity of peripheral sensory neurons caused by P-CTX-1, albeit with their relative contributions differing between 
fibre types.
Unlike skin afferents, all colonic afferents have conduction velocities in the C-fibre range24,25. Using an 
ex-vivo colonic afferent preparation, we investigated the effects of P-CTX-1 on colonic nociceptive afferents that 
respond at noxious levels of distension or high intensity circular stretch and are therefore likely to signal “nocic-
eptive” events26. We found that P-CTX-1 (1 nM) potently activated 74% of colonic nociceptors (14/19) as well as 
recruiting a population of ‘silent nociceptors’ (47%, 9/19 preparations) (Fig. 6g). Consistent with the results on 
C-fibres in the skin-nerve preparation, incubation with the NaV1.8 inhibitor A803467 (10 μ M) abolished P-CTX-
1-induced action potential firing in all colonic nociceptors tested (7/7) (Fig. 6h).
Multiple sodium channel isoforms mediate the in vivo actions of P-CTX-1. We recently estab-
lished an animal model of ciguatera based on the intraplantar administration of P-CTX-1 in mice and showed 
that ciguatoxin-induced cold allodynia is mediated through TRPA1-expressing C-fibres and involves NaV1.89. 
However, whilst we have shown that both TTX-s and TTX-r NaV isoforms contribute to increased neuronal excit-
ability evoked by P-CTX-1, the relative contribution of NaV1.1–1.9 to the symptomatology of ciguatera remains 
unresolved. We thus sought to assess the in vivo contribution of individual NaV isoforms to P-CTX-1-induced 
pain and gastrointestinal effects in relevant murine models.
P-CTX-1-induced spontaneous dermal pain behaviours are mediated by NaV1.6 and 
NaV1.7. Cold allodynia is a pathognomonic symptom of ciguatera and occurs in up to 94% of ciguatera 
sufferers. However, ciguatera is also associated with a number of non-thermally evoked painful dysaesthesias 
attributable to the direct effects of ciguatoxin on NaV channels expressed on peripheral sensory neurons, includ-
ing arthralgias, myalgias, proctalgia, odontalgia, dysuria and dyspareunia. Indeed, intracutaneous adminis-
tration of P-CTX-1 in humans elicits an axon reflex flare and spontaneous pain; effects that also occur after 
intraplantar administration of P-CTX-1 in mice9,27. In order to determine the NaV isoforms contributing to the 
ciguatoxin-induced in vivo effects, we first assessed the effect of local administration of TTX (2 μ M) on P-CTX-
1-induced dermal pain behaviours. To enable assessment of TTX effects on both spontaneous pain behaviours 
as well as cold allodynia, we first administered P-CTX-1 (10 nM; 20 μ l) by intraplantar injection and assessed 
nocifensive behaviours at 32 °C for 10 min. A subsequent intraplantar injection of TTX (2 μ M, 20 μ l; 6.6 ± 3.9 
flinches/5 min) almost completely reversed spontaneous pain behaviours compared with intraplantar injec-
tion of saline (20 μ l; 96.2 ± 8.5 behaviours/5 min) but only partially reversed cold allodynia assessed at 15 °C 
(Saline, 67.8 ± 10.1 behaviours/5 min; TTX, 35.8 ± 7.1 behaviours/5 min) (Fig. 7a). Consistent with the profound 
effect of TTX, which was also observed when co-administered with P-CTX-1 (5 nM, 40 μ l, 95.6 ± 9.1 behav-
iours/5 min; TTX (1 μ M), 7.1 ± 1.3 behaviours/5 min; p < 0.01), treatment with the NaV1.8 inhibitor A803467 
(10 μ M, 105.7 ± 9.4 behaviours/5 min) had no effect on P-CTX-1-induced pain behaviours (Fig. 7b). Similarly, 
P-CTX-1-induced pain behaviours were also unchanged after co-administration of the NaV1.1/1.2 inhibi-
tor TIIIA (10 μ M; 125.7 ± 31.1 behaviours/5 min), while intraplantar administration of the NaV1.6 inhibitor 
GIIIA (10 μ M; 19.0 ± 10.1 behaviours/5 min; p < 0.01) significantly reduced P-CTX-1-induced pain behaviours 
(Fig. 7b). In addition, the selective NaV1.7 inhibitor Pn3a (3 μ M; 7.7 ± 5.7 behaviours/5 min; p < 0.01) was also 
effective at reducing ciguatoxin-induced pain behaviours (Fig. 7b). Overall, these data suggest that the P-CTX-1 
effects on TTX-s NaV isoforms, in particular NaV1.6 and NaV1.7, are associated with symptoms of spontaneous 
(non-stimulus-induced) pain, while TTX-r isoforms contribute to cold allodynia.
Ciguatoxin-induced gastrointestinal sensory disturbances are mediated predominantly by 
NaV1.8. In order to delineate the NaV isoforms contributing to ciguatoxin-induced gastrointestinal distur-
bances, we established a model of P-CTX-1-induced abdominal pain. Consistent with the excitatory effect of 
P-CTX-1 on colonic nociceptors (Fig. 6g,h), intracolonic administration of P-CTX-1 (1 nM, 100 μ l) resulted 
in the activation of dorsal horn neurons within the thoracolumbar spinal cord, as identified by pERK immu-
noreactivity (Fig. 7c). There was a significantly greater number of pERK-IR neurons following intracolonic 
P-CTX-1 compared to vehicle (Fig. 7d,e). The pERK-IR neurons activated by P-CTX-1 are primarily located 
within the superficial dorsal horn laminae I and V, indicating the activation of nociceptive processing pathways 
within the spinal cord. In order to evaluate behavioural changes associated with intracolonic administration 
(1 μ M). (c) Representative recording of a C-fibre unaffected by Pn3a (1 μ M), GIIIA (10 μ M) and TTX (1 μ M)  
and silenced by the NaV1.8 inhibitor A803467 (10 μ M). (d) Effect of P-CTX-1 (0.5 nM) on single A-fibres 
recorded from a skin-saphenous nerve preparation in the mouse. Selective inhibitors of either NaV1.7 (Pn3a, 
1 μ M) or NaV1.6 (GIIIA, 10 μ M) almost completely silenced P-CTX-1-induced action potential firing in 
A-fibres. Each data point represents the number of action potentials/5 min from a single A-fibre receptive field. 
(e) Representative recording of an A-fibre silenced by Pn3a (1 μ M) and (f) GIIIA (10 μ M). (b,c and e,f) Each 
data point represents a single action potential and is plotted as a function of instantaneous frequency (1/s) to 
represent the time elapsed since the previous action potential. Arrows indicate time points of superfusion with 
compounds. (g) P-CTX-1 (1 nM) is a potent activator of colonic nociceptors (activating 14/19 afferents) and 
also recruits silent afferents (9/19 afferents). (h) Pre-incubation with the NaV1.8 blocker A803467 (10 μ M for 
15 min) prevents P-CTX-1-induced firing of colonic nociceptors (7/7 afferents tested). Data are presented as 
mean ± SEM. Statistical significance was determined using (a) One-way ANOVA with Friedman post-hoc test 
or (d) student’s matched observations t-test and defined as p < 0.05 (*).
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Figure 7. Multiple NaV isoforms mediate the in vivo effects of P-CTX-1. (a) Intraplantar injection of 
P-CTX-1 in C57BL/6 mice causes spontaneous pain behaviours at 32 °C which are completely blocked by 
local administration of TTX (2 μ M). Cold allodynia evoked at 15 °C is partially reduced by TTX. (n = 5/
group) (b) At ambient temperature, P-CTX-1-induced nocifensive behaviours were significantly decreased 
by co-administration of TTX (1 μ M), the selective NaV1.7 inhibitor Pn3a (3 μ M) and the NaV1.6 inhibitor 
GIIIA (10 μ M), but not the NaV1.8 inhibitor A803467 (10 μ M) or the NaV1.1/1.2 inhibitor TIIIA (10 μ M). 
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of P-CTX-1, we assessed exploring and grooming behaviours using an automated rodent behavioural analysis 
platform (Behavioral Spectrometer, Biobserve, New Jersey, USA). Compared with administration of saline, intra-
colonic P-CTX-1 led to a significant increase (p < 0.05) in still (Fig. 7f) and grooming (Fig. 7g) behaviours as well 
as a significant decrease (p < 0.05) in orienting (Fig. 7h), rearing (Fig. 7i), walking (Fig. 7k), trotting (Fig. 7l) and 
running (Fig. 7m). As the selective NaV1.8 inhibitor A803467 blocked P-CTX-1-induced action potential firing 
of colonic nociceptors in our ex vivo preparation (Fig. 6), we tested the effect of A803467 on changes in P-CTX-
1-induced behaviours. Consistent with a major role for TTX-r isoforms, specifically NaV1.8, in visceral pain, 
A803467 significantly reversed all behavioural deficits, while concomitant intracolonic administration of TTX 
(100 nM) did not fully reverse P-CTX-1-induced behaviours (Fig. 7f–m).
To gain further insight into the mechanisms underlying the dominant role of NaV1.8 in mediating the P-CTX-
1-induced visceral effects, we next assessed expression of NaV1.6, NaV1.7 and NaV1.8 in whole thoracolumbar 
(TL) DRG (Fig. 7n) and found that NaV1.8 was the most highly expressed NaV isoform, followed by NaV1.7 and 
NaV1.6. Single cell RT-PCR expression analysis within individual retrogradely labelled colonic DRG neurons 
revealed that NaV1.6 was expressed in 63% (15/24), NaV1.7 expressed in 100% (24/24) and NaV1.8 expressed in 
88% (21/24) of thoracolumbar colonic DRG neurons (Fig. 7o). Thus, the high and nearly ubiquitous expression of 
NaV1.8 in colonic DRG neurons provides an explanation for the apparent functional selectivity of an essentially 
non-selective NaV activator toxin like P-CTX-1.
Discussion
Ciguatera is a circumtropical ichthyosarcotoxism linked to the consumption of fish contaminated by the cigua-
toxins; heat-stable polyethers that activate neuronal NaV isoforms to cause neuronal hyper-excitability. The dis-
ease is endemic in the Pacific, Caribbean and Indian Oceans and presents with predominantly gastrointestinal 
and sensory disturbances, muscle weakness, as well as cardiovascular effects in severe poisonings1. While it is 
established that these manifestations of ciguatoxin poisoning are likely attributable to activation of NaV isoforms 
expressed in sensory neurons, cardiac tissue and skeletal muscle, the effects of ciguatoxin on individual NaV 
isoforms and their relative contribution to the symptomatology of ciguatera has not been assessed systemati-
cally. Therefore, we determined the specific effects of P-CTX-1 on all NaV isoforms, as well as the contribution 
of individual NaV isoforms to action potential firing in dermal and visceral afferents. We also determined the 
NaV isoforms contributing to ciguatoxin-induced pain of dermal and gastrointestinal origin. Overall, our results 
suggest that the effects of P-CTX-1 on NaV1.8 are particularly important in the majority of C-fibre nociceptors, 
while TTX-s NaV isoforms, in particular NaV1.6 and NaV1.7, contribute to P-CTX-1-mediated effects on A-fibres.
P-CTX-1 is the most potent ciguatoxin congener and is thought to be responsible for the majority of symp-
toms in the Pacific28. Ingestion of fish contaminated with 0.1 ppb ciguatoxin is known to cause ciguatera, with the 
average pathogenic dose causing symptoms in humans estimated at 2 ng/kg29. In mice, intravenous dosing with 
130 ng/kg P-CTX-1 was associated with peak plasma levels of approximately 60 pg/mL30, however unfortunately, 
data on plasma ciguatoxin levels in human ciguatera patients is not available.
Estimation of the concentration of the ciguatoxins in tissue is even more difficult, particularly in light of the 
high lipophilicity of the toxins and the corresponding large volume of distribution31. Based on human experi-
ments assessing sensory effects of P-CTX-1 after intracutaneous administration, concentrations ranging from 
1–10 nM are sufficient to elicit symptoms of itching, burning pain and cold allodynia9,27. Given the rapid emer-
gence of effects after local administration, as well as the quasi-irreversible binding to NaV channels, losses due to 
redistribution are likely minimal, suggesting that the concentrations of P-CTX-1 used for in vitro studies in our 
experiments are highly relevant to human disease.
We found that P-CTX-1 is approximately equipotent at all human NaV isoforms. Although P-CTX-1 can be 
considered a relatively non-selective NaV activator in terms of potency, we did observe significant functional 
differences that were NaV subtype dependent.
While the voltage-dependence of activation was shifted to more hyperpolarising potentials at all NaV sub-
types, a hyperpolarising shift in the voltage-dependence of steady-state fast inactivation only occurred at NaV1.2, 
NaV1.3 and NaV1.9. These observed hyperpolarising shifts could lead to decreased availability of these isoforms 
for action potential generation and propagation in vivo. In addition, P-CTX-1 induced a significantly accelerated 
(n = 4–12 animals/group). (c) In vivo intra-colonic administration of P-CTX-1 (1 nM) activates nociceptive 
endings within the wall of the colon, leading to signalling into the dorsal horn and activation of neurons within 
the thoracolumbar spinal cord, as identified by pERK immunoreactivity (arrows). pERK-IR neurons were 
predominantly located in the nociresponsive superficial dorsal horn (laminae I) and also in laminae V.  
(d) Intracolonic administration of vehicle alone did not induce dorsal horn neuron pERK immunoreactivity. 
(e) Group data showing that P-CTX-1 evoked significant dorsal horn neuron activation (**p < 0.005) compared 
with vehicle administered mice (n = 3–4 animals/group). (f–m) A novel mouse model of P-CTX-1-induced 
visceral pain. Intracolonic administration of P-CTX-1 (50 μ l, 10 nM) caused a significant (*p < 0.05 compared 
with Saline control) increase in (f) still and (g) grooming behaviours as well as a significant (*p < 0.05 compared 
with Saline control) decrease in (h) orienting, (i) rearing, (k) walking, (l) trotting and (m) running. These 
behavioural changes were reversed by A803467 (100 mg/kg; #p < 0.05 compared with P-CTX-1) but not 
intracolonic TTX (100 nM). (n = 6–12 animals/group) (n) NaV1.8 is the most highly expressed NaV isoform 
in whole thoracolumbar DRG (n = 5 animals/target). (o) NaV1.8 is highly expressed within thoracolumbar 
DRG neurons innervating the colon (88%: 21 out of 24 colonic neurons). Data are presented as mean ± SEM. 
Statistical significance (defined as p < 0.05) was determined using student’s t-test (a,e) or One-way ANOVA 
with Sidak’s multiple comparison (b,f–m).
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inactivation at NaV1.1, NaV1.2 and NaV1.3. In contrast, a significant depolarising shift in steady-state fast inac-
tivation was observed for NaV1.4. Similar effects were also reported for the N440K NaV1.4 mutation, which is 
associated with paradoxical myotonia32, suggesting that the increase in window current effected by concomitant 
shifts in the voltage-dependence of activation and inactivation of NaV1.4 may contribute to ciguatoxin-induced 
muscle weakness.
P-CTX-1 also caused a small persistent current at NaV1.3, which may contribute to the slightly increased 
activity at this isoform we observed in the membrane potential assay. This activity may also explain our previous 
observation that P-CTX-1-induced responses in the neuroblastoma cell line SH-SY5Y are mediated predom-
inantly through NaV1.327. However, as NaV1.3 is typically expressed at high levels during development, and is 
reported to be essentially absent from adult rodent DRG neurons, this suggests that effects at NaV1.3 are unlikely 
to contribute substantially to the in vivo symptomatology of ciguatera33. Interestingly, a previous study reporting 
the emergence of a TTX-sensitive leak current after treatment with P-CTX-1 used neonatal DRGs, suggesting that 
this activity may have been mediated by expression of neonatal NaV1.320.
P-CTX-1 had the most pronounced effects at NaV1.8, including a large shift in the voltage-dependence of acti-
vation that was particularly apparent at depolarised potentials, and a significant delay in inactivation. In contrast, 
P-CTX-1 did not affect the voltage-dependence of fast inactivation of NaV1.8. These effects are consistent with 
our observation of increased activation and prolonged active periods observed with single channel recordings, 
and the reported effects of the synthetic ciguatoxin analogue CTX3C on rat NaV1.8 channels, where large leak 
currents as well as a shift in the voltage-dependence of activation occurred, albeit at 10-fold higher concentrations 
and bringing into question whether the native form of CTX3C was synthesised34.
The binding site of the ciguatoxins and brevetoxins, all of which are believed to act at site 5 of the voltage-gated 
sodium channel35,36, is relatively poorly defined. Using elegant photoaffinity labelling experiments of rat brain 
sodium channels, the likely regions involved in binding of brevetoxin were identified as residues in domain I S6 
(Thr400-Lys443; rat NaV1.2 numbering) and the extracellular loop following domain IV S5 (Glu1688 – Lys1735; 
rat NaV1.2 numbering)35.
The domain I binding site appears to be particularly important for high affinity effects of the ciguatoxins on 
NaV1.8, as chimeric channels containing domains I and II from NaV1.4 responded much less to synthetic cigua-
toxin analogues than native NaV1.8, or chimeras incorporating domains I and II from NaV1.834. Interestingly, 
both the domain I and domain IV regions are highly conserved across rodent and human NaV isoforms, perhaps 
explaining at least in part the essentially non-selective effects of P-CTX-1. More subtle, subtype-specific effects 
on channel gating are more difficult to explain with our current knowledge of the ciguatoxin binding site. For 
example, the residues forming site 5 in domain I are identical between human NaV1.1 and NaV1.2, while only 
2 residues (G1727 > K and D1734 > N, NaV1.2 numbering) differ in domain IV. It is currently unclear whether 
these differences could contribute to the observed effect of P-CTX-1 on channel inactivation at NaV1.2, but not 
NaV1.1. An alternate, perhaps more likely, explanation is that additional, as yet undefined, residues outside the 
immediate binding pocket contribute to subtype-specific effects on channel gating.
Adult sensory neurons predominantly express three TTX-sensitive NaV isoforms NaV1.1, NaV1.6, and NaV1.7, 
as well as the TTX-resistant isoforms NaV1.8 and NaV1.937,38. Previous studies have demonstrated that P-CTX-1 
affects both TTX-sensitive and TTX-resistant NaV isoforms in DRG neurons20,21. Accordingly, in the current 
study using cultured DRG neurons, both NaV1.8 and TTX-sensitive isoforms were major contributors to P-CTX-
1-induced responses. However, while P-CTX-1 also affected the voltage-dependence of activation of NaV1.9, 
P-CTX-1-induced responses were unchanged in DRG neurons from NaV1.9−/− animals. Nonetheless, some 
small responses remained in DRG neurons from NaV1.8−/− animals treated with TTX, suggesting that at least 
a small component of Na+ influx induced by P-CTX-1 may be conducted by NaV1.9. Indeed, a small number 
of non-responding individual neurons were observed in cultures from NaV1.9−/− animals. These results suggest 
that, at least at the concentrations assessed here, and perhaps due to CTX’s effects on voltage-dependence of fast 
inactivation, NaV1.9 is not a major contributor to P-CTX-1-mediated effects.
Experiments assessing P-CTX-1-induced action potential firing in C-fibres both from the skin-saphenous 
nerve and colonic preparations revealed a major role for NaV1.8, with the NaV1.8 blocker A803467 significantly 
reducing or blocking firing. While some dermal C-fibres were silenced by TTX, surprisingly few were affected 
by selective inhibition of NaV1.7, suggesting that in the majority of C-fibres, P-CTX-1-induced action potential 
firing is maintained by NaV1.8. This observation is consistent with previous studies reporting a contribution of 
NaV1.8 to more than 80% of the inward membrane current during the rising phase of the action potential39 and 
also a substantial decrease in C-fibre activity in response to P-CTX-1 in fibres from NaV1.8−/− mice9. In terms of 
visceral pathways, the involvement of NaV1.8 in P-CTX-1 induced colonic nociceptor activation is consistent with 
a pronounced role for NaV1.8 in visceral pain, as demonstrated by Nav1.8 −/− mice displaying blunted pain and 
hyperalgesia to intracolonic mustard oil administration40.
We found that P-CTX-1-induced action potential firing in A-fibres was almost completely abolished by selec-
tive inhibition of NaV1.7 and substantially reduced by the NaV1.6 inhibitor GIIIA. These findings are consistent 
with the major contribution of TTX-s NaV isoforms to action potential conduction in these neurons41,42. The 
NaV1.7 findings are intriguing, as NaV1.7 plays a key role in regulating sensory neuron excitability, owing to its 
unique expression pattern, as well as slow closed-state inactivation, which underpins the ability of NaV1.7 to gen-
erate large ramp currents in response to slow depolarisations43. While we could not assess expression of NaV1.7 
in non-responding A-fibres, and distinction of Aβ and Aδ fibres based on conduction velocity is difficult in the 
murine skin-nerve preparation due to the limited length of the saphenous nerve, it seems plausible that nerve 
endings of Aδ fibres expressing NaV1.7 respond to P-CTX-1 with action potential firing, whereas those lacking 
this isoform (presumably Aβ fibres) do not. This conclusion is not only consistent with the hyperpolarising shift 
in the voltage-dependence of activation at NaV1.7 caused by P-CTX-1, which would lead to enhanced neuronal 
excitability and action potential firing, but also expression of NaV1.7 in a significant proportion of high- and 
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low-threshold myelinated Aδ neurons but few, if any, cutaneous myelinated Aα /β low-threshold mechanosen-
sitive units44. Indeed, our results showed that A-fibres responding to P-CTX-1 had slower conduction velocities 
than non-responders. In comparison, NaV1.6 is widely expressed in large diameter DRG neurons of myelinated 
fibres, where it is localised predominantly at the nodes of Ranvier45,46. Thus, the selective activation of some, but 
not all, A-fibres by P-CTX-1 suggests that the relatively minor shift in the voltage-dependence of activation at 
NaV1.6 caused by P-CTX-1 is not sufficient to induce action potential firing, and that the inhibitory actions of 
GIIIA likely arises from the effects on action potential propagation, which depends on NaV1.6 in these fibres.
We have previously shown in humans that the in vivo effects of P-CTX-1 after intradermal injection closely 
resemble the effects elicited by intraplantar injection in mice. This is evidenced by characteristic symptoms of 
spontaneous pain that resolve to reveal cold allodynia upon exposure to cool temperatures9,27. Whilst P-CTX-
1-induced cold allodynia is mediated by TRPA1-expressing nociceptors and involves activation of NaV1.8, the 
contribution of individual NaV isoforms to P-CTX-1-induced spontaneous and visceral pain have not been deter-
mined. In the current study we found that inhibition of P-CTX-1-induced acute dermal pain paralleled the phar-
macology of action potential firing in A-fibres, with both selective NaV1.7 and NaV1.6 inhibition leading to a 
reversal of associated pain behaviours. This likely reflects the pattern of expression of NaV isoforms in the sensory 
nerve endings of skin afferents47, which in turn is determined by the electrophysiological properties of individual 
isoforms, as well as the specific effects of P-CTX-1 on each isoform. Accordingly, in colonic sensory neurons, 
where NaV1.8 was the most highly expressed isoform, inhibition of NaV1.8 by A803467, a subtype-selective small 
molecule blocker, significantly reversed P-CTX-1-induced behavioural effects.
In terms of other NaV isoforms expressed by DRG neurons, NaV1.1 was recently shown to mediate 
mechanically-evoked action potential firing in dermal and colonic sensory neurons48. While P-CTX-1 caused a 
hyperpolarising shift in the voltage-dependence of NaV1.1 activation, it also caused acceleration of inactivation, 
suggesting that the contribution of NaV1.1 to P-CTX-1-induced in vivo effects may be negligible. Indeed, we pre-
viously reported a lack of P-CTX-1-induced mechanical allodynia after intraplantar injection9, consistent with the 
lack of effect of the NaV1.1 inhibitor TIIIA on spontaneous pain observed in this study.
While intraperitoneal injection of P-CTX-1 gives rise to symptoms consistent with visceral hypersensitivity, 
including diarrhoea, writhing and abdominal contractions, potentially confounding effects on global nerve con-
duction velocity make it poorly suited to delineating the pharmacology of ciguatoxin-induced visceral pain49,50. 
In contrast, our model based on intracolonic administration of P-CTX-1, which caused activation of colonic 
nociceptors and activation of nociceptive processing regions in the spinal cord, led to more subtle effects on 
behaviour, including decreased locomotion and exploring behaviours. However, while systemic dosing with 
the NaV1.8 inhibitor A803467 led to a substantial decrease in P-CTX-1-induced behavioural abnormalities, the 
TTX-sensitive NaV isoforms contributing to the in vivo effects of ciguatoxin remain to be determined. A likely 
candidate is NaV1.7, albeit NaV1.1 was recently shown to contribute to visceral mechanical hypersensitivity in 
models of irritable bowel syndrome48. A particularly interesting aspect that remains to be addressed is whether 
oral administration of subtype-selective peptidic NaV inhibitors could ameliorate the gastrointestinal symptoms 
associated with ciguatera.
Finally, while this study focused on the subtype-selective effects of P-CTX-1 on NaV isoforms, the ciguatoxins 
are also known to inhibit K+ channel function. However, while effects on both delayed rectifier and A-type chan-
nels have been reported51, the pharmacology of P-CTX-1 at heterologously expressed K+ channel isoforms has 
not been systematically assessed. Accordingly, the contribution of this alternate pharmacology to the symptom-
atology of ciguatera remains to be determined, particularly since the subtle subtype-specific effects of NaV gating 
are unlikely to fully account for the pathognomonic symptom of cold allodynia.
In conclusion, we have shown that in terms of potency P-CTX-1 is a relatively non-selective activator of 
human NaV subtypes that shifts the voltage-dependence of activation to more hyperpolarising potentials for 
all NaV subtypes. However, P-CTX-1 induces distinct functional effects on NaV subtypes, including increas-
ing the inactivation time constant at NaV1.8, increasing the slope factor of the conductance-voltage curve at 
NaV1.7, and increasing the peak current at NaV1.6. Correspondingly, the in vivo effects induced by P-CTX-1 
appear to be driven predominantly by NaV1.6, NaV1.7 and NaV1.8. Thus, we conclude that the behavioural effects 
associated with ciguatera reflect the expression pattern of NaV isoforms in peripheral nerve endings, as well 
as their CTX-induced contribution to membrane depolarisation, action potential initiation and propagation. 
Accordingly, selective inhibitors of NaV1.7 and NaV1.8, and to a lesser extent NaV1.6 which is also found in motor 
nerves, may be promising therapeutics for management of the symptomatology of ciguatera in the clinic.
Materials and Methods
Ethics and animals. Ethical approval for experiments involving animals was obtained from the local ani-
mal ethics committees at the University of Queensland, the University of Adelaide, the South Australian Health 
and Medical Research Institute (SAHMRI) and the University of Erlangen in accordance with local legislation. 
Experiments involving animals were conducted in accordance with the Animal Care and Protection Act Qld 
(2002), the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, 8th edition (2013) 
and the International Association for the Study of Pain Guidelines for the Use of Animals in Research. Adult male 
C57BL/6, NaV1.8−/− and NaV1.9−/− mice (John N. Wood, University College London, London, UK; congenic 
to C57BL/6 or backcrossed for at least 6 generations on the C57BL/6 background, respectively) and their age-
matched litter controls were used. All animals were genotyped using previously reported primers52,53.
Animals were randomly assigned to treatment groups using a stratified randomisation strategy and all asses-
sors were blinded to genotype or treatment. General health and wellbeing was monitored daily and no animals 
were withdrawn from the study. Sample sizes of each experiment are detailed in the figure legends of the corre-
sponding figure.
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Chemicals and drugs. P-CTX-1 was isolated and purified from moray eel viscera to > 95% purity as pre-
viously described by Lewis et al.28 and stored as a concentrated stock in 50% methanol/50% H2O. P-CTX-1 
was diluted in relevant assay buffers in the presence of 0.1% bovine serum albumin Cohn Fraction V (BSA) 
(BioScientific, Kirrawee, NSW, Australia) to avoid losses to plastic surfaces. Veratridine was obtained from Ascent 
Scientific (Bristol, United Kingdom). All other reagents were obtained from Sigma Aldrich (Castle Hill, NSW, 
Australia) unless otherwise specified.
Cell Lines and culture. Stable human embryonic kidney cells (HEK293) constitutively expressing human 
NaV isoforms NaV1.1–1.8 (SB Biomedical, Glasgow, United Kingdom). These cells were routinely maintained 
in minimal essential medium (MEM) (Sigma-Aldrich, Australia) supplemented with 10% foetal bovine serum 
(FBS) (Bovogen Biologicals, France), 2 mM L-glutamine and selection antibiotics as recommended by the manu-
facturer. For electrophysiological studies, CHO cells stably expressing hNaV1.8 in a tetracycline-inducible system 
(Chantest, OH, USA) were cultured in Ham’s F-12 containing 10% v/v foetal bovine serum and selection antibi-
otics as recommended by the manufacturer. To induce hNaV1.8 expression, cells were cultured in the presence 
of tetracycline (1 μ g/mL) for 24 h at 27 °C. All cell lines were grown in a humidified 5% CO2 incubator at 37 °C, 
grown to 70–80% confluence, and passaged every 3–4 days using TrypLE Express (Invitrogen). HEK293 stably 
expressing hNaV1.9 were generated and maintained by Icagen Inc. (Durham, NC, USA) as described54.
FLIPRTetra Membrane Potential Assay. Activity of P-CTX-1 and Pn3a at hNav1.1–1.8 was assessed using 
a fluorescent plate reader (FLIPRTetra) membrane potential assay as previously described55. In brief, cell lines 
(HEK293 Nav1.1–1.8) were plated on 384-well black-walled imaging plates (Corning) at a density of 10 000–15 0000 
cells per well 48 hours before loading with 20 μ L of red membrane potential dye (proprietary formulation) 
(Molecular Devices, Sunnyvale, CA). Cells were incubated with the membrane potential dye for 30 min at 37 °C 
before the addition of P-CTX-1 and veratridine or deltamethrin by the FLIPRtetra system. After the first addition 
(P-CTX-1), fluorescence was measured (excitation 515–545 nm; emission: 565–625 nm) for a period of 5 min to 
determine the effects of P-CTX-1 alone. Following this 5 min exposure, veratridine (5–20 μ M) or deltamethrin 
(100 μ M) was added and fluorescence was measured for a further 5 min. Data was recorded and converted to 
response over baseline using Screenworks 3.2.0.14. For concentration-response curves, maximum values from 
the response after addition of agonist were plotted against agonist concentration and a 4-parameter logistic Hill 
equation was fitted to the data using GraphPad Prism Version 6.00 (San Diego, CA).
Electrophysiology. Electrophysiology (NaV1.1–1.8). For NaV1.1–1.8, whole-cell patch-clamp experiments 
were performed on a QPatch-16 automated electrophysiology platform (Sophion Bioscience, Ballerup, Denmark) 
using 16-channel planar patch chip plates (QPlates; Sophion Bioscience) with a patch hole diameter of 1 μ m 
and resistance of 2 ± 0.02 MΩ . Cell positioning and sealing parameters were set as follows: positioning pressure 
− 60 mbar, minimum seal resistance 0.1 GΩ, holding potential − 100 mV, holding pressure − 20 mbar. Whole-cell 
currents were filtered at 5 kHz and acquired at 25 kHz.
HEK-293 cells expressing hNaV1.1–1.7 or tetracycline inducible CHO cells expressing hNaV1.8 (as 
NaV1.8-HEK cells are unsuitable for patch clamping) were harvested at 70–80% confluence, by washing with 
Ca2+ and Mg2+ free Dulbecco’s phosphate-buffered saline and incubating with Detachin (Bio-Scientific, NSW, 
Australia) at 37 °C for 2–5 min. Dissociated cells were then resuspended in Ex-Cell ACF CHO Medium with 
25 mM HEPES (Sigma-Aldrich, NSW, Australia) and transferred to the QStirrer (Sophion) and allowed to recover 
for 30 min. The extracellular solution contained in mM: NaCl 145, KCl 4, CaCl2 2, MgCl2 1, HEPES 10 and glu-
cose 10. The pH was adjusted to 7.4 with NaOH and osmolarity was adjusted with sucrose to 305 mOsm. The 
intracellular solution contained in mM: CsF 140, EGTA/CsOH 1/5, HEPES 10 and NaCl 10. The pH was adjusted 
to 7.3 with CsOH and osmolarity adjusted with sucrose to 320 mOsm. P-CTX-1 was diluted in extracellular solu-
tion with 0.1% BSA to a concentration of 10 nM and incubated for 5 min. All P-CTX-1 effects were compared to 
pre-toxin control parameters within the same cell.
Current (I)–voltage (V) relationships were obtained with a holding potential of − 80 mV followed by a 
pre-pulse of −100 mV for 50 ms and a series of 50 ms step pulses that ranged from − 80 to + 60 mV in 5 mV 
increments before returning to a holding potential of − 80 mV (repetition interval 5 s). Conductance-voltage 
relationships were obtained by calculating the conductance (G) at each voltage (V) using the equation G = I/
(V − Vrev), where Vrev is the reversal potential. Conductance-voltage curves were fitted with a Boltzmann equa-
tion: GNa = GNa,max/1 + exp [(Vm − V1/2)/k], where GNa is the voltage-dependent sodium conductance, GNa,max is 
the maximal sodium conductance, V1/2 is the potential at which activation is half-maximal, Vm is the membrane 
potential, and k is the slope factor.
Voltage dependence of steady-state fast inactivation was measured using a series of 500 ms pre-pulses, ranging 
from − 120 to − 10 mV in 10 mV increments, followed by a 20 ms pulse of − 20 mV for NaV1.1–1.7 and + 10 mV 
for NaV1.8 to assess the available non-inactivated channels (repetition interval 30 s). Peak inward currents (I) 
were normalised to the maximal inward current (Imax) and fitted using a Boltzmann equation: I/Imax = 1/(1 + exp 
[(Vm − V1/2)/k)], where Imax is the maximal inward current, V1/2 is the half-maximal sodium current, Vm is the 
pre-conditioning pulse potential, and k is the slope factor.
Time to peak, fast inactivation time constants and persistent current were determined by a single-pulse pro-
tocol, using a holding potential of − 80 mV, followed by a pre-pulse of − 100 mV for 50 ms and then a 50 ms pulse 
of − 20 mV for NaV1.1–1.7 and + 10 mV for NaV1.8. Time to peak was measured from pulse onset to maximal 
current, fast inactivation time constants were calculated by fitting current decay traces with a single exponential 
function, and persistent current was determined as the mean current between 40 and 50 ms after pulse onset.
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Electrophysiology (NaV1.9). For hNaV1.9, whole-cell patch-clamp experiments were performed by Icagen Inc 
(Durham, NC, USA) on a PatchXpress automated electrophysiology platform (Molecular Devices, Sunnyvale, 
CA, USA) using HEK-293 cells stably expressing hNaV1.9. The extracellular solution for these studies contained 
in mM: NaCl 135, KCl 5.4, CaCl2 2, MgCl2 1, HEPES 10 and glucose 5. The pH was adjusted to 7.4 with NaOH 
with a measured osmolarity of 300 mOsm. The intracellular solution contained in mM: CsF 135, EGTA 5, CsCl 
10, HEPES 10 and NaCl 5. The pH was adjusted to 7.4 with CsOH with a measured osmolarity of 298 mOsm. 
P-CTX-1 (1 nM) was diluted in extracellular solution with 0.1% BSA to a concentration of 1 nM and incubated 
for 5 min. All P-CTX-1 effects were compared to pre-toxin control parameters within the same cell. Current 
(I)–voltage (V) curves were obtained with a holding potential of − 140 mV, then a series of 100 ms step pulses 
that ranged from − 140 to 0 mV in 10 mV increments, followed by a 20 ms pulse of − 40 mV to assess the availa-
ble non-inactivated channels (repetition interval 10 s). Conductance-voltage curves and voltage dependence of 
steady-state fast inactivation curves were then calculated and fitted as described above.
Single Channel Recordings. Single channel recordings were done in the excised, outside-out patch configura-
tion at room temperature (22 ± 1 °C). Currents were elicited by stepping the clamped voltage from − 100 mV to 
− 20 mV before and after exposing the recorded path to 1 nM P-CTX-1 for 10–12 min. The intracellular solution 
was composed of (in mM): 145 CsCl, 2 CaCl2, 2 MgCl2, 10 HEPES, and 5 EGTA, adjusted to pH 7.4 with CsOH. 
The control extracellular solution was composed of (in mM): 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 
10 D-glucose, adjusted to pH 7.4 with NaOH. Bovine serum albumin at 0.01% was added to all working extra-
cellular solutions.
Recording electrodes were fire polished and had resistances of 5–9 MΩ when filled with intracellular solution. 
Single channel currents were recorded using an Axon 200B amplifier (Molecular Devices), filtered (− 3 dB, 4-pole 
Bessel) at 5 kHz and sampled at 20 kHz. Currents were filtered offline to 2 kHz for making figures. The single 
channel active period durations were estimated using QuB software, from idealising events longer that 70 μ s 
(dead time). Single channels activations were defined by a critical shut duration (tcrit) of 5–10 ms (large ampli-
tude) and 20–70 ms (small amplitude). tcrit was calculated for each patch by equalising the area under the longest 
two shut components in the shut dwell histograms. Data are presented as mean ± SEM from 3–5 patches in all 
recording conditions.
Retrograde tracing of colonic DRG neurons. Cholera toxin subunit B conjugated to AlexaFluor 488 
(CTB-488; Invitrogen, Carlsbad, CA) was injected at three sub-serosal sites within the wall of the distal colon of 
C57BL/6 mice. After 4 days, animals were humanely killed by CO2 inhalation for subsequent DRG removal and 
culture56,57.
Dorsal root ganglion isolation and culture. Dorsal root ganglion neurons were isolated and cultured as 
previously described9,25,48,58. For Na+ imaging experiments, DRGs from T1-L6 were isolated from adult male C57/
BL6 mice, male NaV1.8−/− mice or male NaV1.9−/− mice euthanised by CO2 inhalation and collected in DMEM 
supplemented with 50 μ g/ml gentamicin (Sigma), 100 U/ml penicillin, 100 ug/ml streptomycin and 0.25 μ g/ml 
amphotericin B (Life Technologies). DRGs were then incubated for 30 min at 37 °C and 5% CO2 in dissociation 
media containing 1 mg/ml collagenase (Sigma) and 0.1 mg/ml protease (Sigma). After three wash steps, cells were 
triturated through a flame-polished glass Pasteur pipette and cultured for 24 h in TNB 100 solution supplemented 
by TNB 100 lipid-protein-complex, 1 nM NGF, 100 μ g/ml streptomycin and penicillin (all from Biochrom, Berlin, 
Germany) and 200 μ g/ml glutamine (Life Technologies) or Neurobasal medium supplemented with B27, 1 nM 
NGF and 100 μ M glutamine (all from Life Technologies, Mulgrave, Vic, Australia) for high content imaging.
For Ca2+ imaging experiments, T10-L1 DRGs from retrogradely traced mice were surgically removed and 
were digested with 4 mg/mL collagenase II (GIBCO, Life Technologies) plus 4 mg/mL dispase (GIBCO) for 30 min 
at 37 °C, followed by 4 mg/mL collagenase II for 10 min at 37 °C. Neurons were then mechanically dissociated 
into a single-cell suspension via trituration through fire-polished Pasteur pipettes. Neurons were resuspended in 
DMEM (GIBCO) containing 10% FCS (Invitrogen), 2 mM L-glutamine (GIBCO), 100 μ M MEM non-essential 
amino acids (GIBCO), 100 mg/ml penicillin/streptomycin (Invitrogen) and 100 ng/ml NGF (Sigma). Neurons 
were spot-plated on coverslips coated with poly-D-lysine (800 μ g/ml) and laminin (20 μ g/ml) and maintained at 
37 °C in 5% CO2. Comparisons were made between retrogradely labeled colonic DRG neurons and non-labelled 
DRG neurons.
Na+ and Ca2+ imaging of cultured DRG neurons. To assess the effect of P-CTX-1 (1 nM) on Na+ and 
Ca2+ influx in cultured DRG neurons, cells were plated on PDL-coated glass coverslips and after 24 hours in 
culture incubated with 10 μ M Sodium Green-AM (Na+ indicator) or 2.5 μ M Fura2-AM (Ca2+ indicator) respec-
tively. Sodium Green -AM was incubated for 1 h at 37 °C while Fura2-AM was incubated for 30 min at room 
temperature in extracellular fluid (ECS, composition: NaCl 145 mM, KCl 5 mM, CaCl2 1.25 mM, MgCl2 1 mM, 
glucose 10 mM, HEPES 10 mM) containing 0.02% (v/v) pluronic acid in DMSO. After a brief wash, coverslips 
were transferrerd to the recording chamber and Na+ or Ca2+ responses were measured at room temperature 
(~22 °C). Sodium Green was excited at 507 nm with a Polychrome V monochromator (Till Photonics). Images 
were exposed for 200 μ s and acquired at a rate of 1 Hz with a peltier-cooled slow-scan CCD camera system (Imago 
Sensicam QE, Till Photonics). Data were recorded and further analysed using TILLvisION 4.0.1.3 software (Till 
Photonics). After a baseline read with extracellular solution or TTX (300 nM), DRG neurons were stimulated 
with 1 nM P-CTX-1, followed by a final stimulation with 30 mM KCl to identify viable neurons. Na+ responses 
were analysed as the total fluorescence with responses > 1000 fluorescence units defined as responders.
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Fura-2 was excited at 340 and 380 nm using a Nikon TE300 Eclipse microscope equipped with a Sutter DG-4/
OF wavelength switcher, Omega XF04 filter set for Fura-2, Photonic Science ISIS-3 intensified CCD camera, and 
Universal Interface Card MetaFluor software. Fluorescence images were obtained every 20 s using a 20x objective. 
Data were recorded and further analysed using Xcellence software (Olympus) after a baseline fluorescence read 
with extracellular solution or in the presence of TTX (500 nM). Colonic DRG neurons (identified by the presence 
of the 488 tracer) were stimulated with 1 nM P-CTX-1, followed by a final stimulation with 40 mM KCl to identify 
viable neurons. Ca2+ responses were presented as the fluorescence ratio 340/380. Ca2+ maximum peak responses 
elicited by P-CTX-1 were calculated by subtracting maximum Fura-2 fluorescence (340/380) values to the Fura-2 
fluorescence (340/380) values before P-CTX-1 addition.
Single fibre recordings using the murine skin-saphenous nerve preparation. To characterise the 
pharmacology of P-CTX-1-induced effects on C- and A-fibre afferents, we used extracellular recordings from the 
murine skin-saphenous nerve preparation as previously described59. The hairy skin of the dorsal hind paw and lower 
leg of male adult C57BL/6 mice was carefully dissected together with the saphenous nerve, placed in an organ bath 
chamber with the epithelial side secured in a downward position using white soft paraffin and continuously per-
fused with carbogenated SIF (composition (mM): NaCl (107.8), KCl (3.5), MgSO4 (0.69), NaHCO3 (26.2), NaH2PO4 
(1.67), Na-gluconate (9.64), glucose (5.55), sucrose (7.6) and CaCl2 (1.53); pH 7.3). The desheathed saphenous 
nerve was placed on a mirror in an adjacent paraffin oil-filled recording chamber and teased into filaments until 
recordings from single, mechanically excitable receptive fields was achieved. Fibres were classified according to con-
duction velocity (C-fibre < 1 m/s, A-fibre 1.6–12 m/s) after electrical stimulation of the receptive field with a bipolar 
teflon coated steel microelectrode (impedance ~ 1 MΩ). The dermal receptive field was then isolated using a plastic 
ring, and after a 5 min recording period to determine baseline activity, P-CTX-1 (0.5 nM) was perfused at a rate of 
5 mL/min at 32 °C for up to 30 min. Fibres without an increase in spontaneous action potential discharge rate after 
30 min were considered non-responders. For responding fibres, once spontaneous action potential firing was stable 
for at least 5 min, NaV subtype-selective inhibitors were sequentially added every 15 min to the perfusate to achieve 
final concentrations of the NaV1.7 inhibitor Pn3a (1 μ M), the NaV1.6 inhibitor GIIIA (10 μ M), TTX (1 μ M) and the 
NaV1.8 inhibitor A803467 (10 μ M). Data was recorded and analysed using DAPSYS (version 8).
Single fibre colonic afferent recordings using the murine colon-splanchnic nerve prepara-
tion. C57BL/6 male mice were humanely killed by CO2 inhalation. The colon and rectum with attached mes-
entery and splanchnic nerves were removed and afferent recordings performed as described previously24,25,60. 
Briefly, the colon was removed and pinned flat, mucosal side up, in a specialised organ bath. The colonic compart-
ment was superfused with a modified Krebs solution (in mM: 117.9 NaCl, 4.7 KCl, 25 NaHCO3, 1.3 NaH2PO4, 1.2 
MgSO4, 2.5 CaCl2, 11.1 D-glucose), bubbled with carbogen (95% O2, 5% CO2) at a temperature of 34 °C. All prepa-
rations contained the L-type calcium channel antagonist nifedipine (1 μ M) to suppress smooth muscle activity and 
the prostaglandin synthesis inhibitor indomethacin (3 μ M) to suppress potential inhibitory actions of endoge-
nous prostaglandins. The nerve bundle was extended into a paraffin-filled recording compartment in which finely 
dissected strands were laid onto a mirror, and single fibre placed on the platinum recording electrode. Action 
potentials generated by mechanical or chemical stimuli to the colon’s receptive field, pass through the fibres into a 
differential amplifier, filtered, sampled (20 kHz) using a 1401 interface (Cambridge Electronic Design, Cambridge, 
UK) and stored on a PC for off-line analysis. P-CTX-1 (1 nM) was added for 5 min via a small metal ring placed 
over the receptive field of interest in selective experiments the NaV1.8 channel inhibitor A803467 (10 μ M) was 
pre-incubated for 10 min prior co-incubation with P-CTX-1. This route of administration has been previously 
shown to reproducibly activate afferents25,48,61. Action potentials were analysed off-line using the Spike 2 wavemark 
function and discriminated as single units on the basis of distinguishable waveform, amplitude and duration.
Colonic afferent classification. Receptive fields were identified by systematically stroking the mucosal 
surface with a still brush to activate all subtypes of mechanoreceptors. Categorisation of afferents properties 
was in accordance with our previously published classification system59,62. Briefly, splanchnic nociceptors have 
high-mechanical activation thresholds, responding to noxious distension (40 mm Hg), stretch (≥ 7 g) or von Frey 
hair filaments (2 g) but do not respond to fine mucosal stroking (10 mg von Frey hairs; vfh).
Animal model of P-CTX-1-evoked nocifensive behaviours. To assess the pharmacology of P-CTX-
1-evoked nocifensive behaviours, a single dose of P-CTX-1 diluted in sterile saline was administered by subcu-
taneous injection to the hind paw (intraplantar, i.pl., 40 μ l, 10 nM) under brief isoflurane (3%) anaesthesia. To 
assess the effect of Pn3a on NaV1.7-mediated responses, a single dose of the selective NaV1.7 activator OD1 (40 μ l, 
300 nM) was administered by i.pl. injection under brief isoflurane (3%) anaesthesia together with increasing 
concentrations of Pn3a (Suppl. Fig. 1). Nocifensive behaviours including paw lifting, licking and flinching were 
rated by a blinded observer over a 5 min period. To assess the effects of pharmacological modulators on the devel-
opment of P-CTX-1 induced pain, compounds were either administered as a second intraplantar injection (TTX, 
2 μ M) or co-administered with P-CTX-1 by i.pl. injection as appropriately concentrated solutions (TTX, 1 μ M; 
A803467, 10 μ M; Pn3a 1 μ M; GIIIA, 10 μ M). To assess cold allodynia in ciguatoxin-treated animals, mice were 
placed on a temperature-controlled Peltier plate (Ugo Basile, Comerio, Italy) once spontaneous pain behaviours 
subsided to < 10 counts/5 min and the number of paw shakes, lifts, licks or flinches was quantified over a 5 min 
period at 15 °C. Injection of equal volumes of sterile saline did not elicit any nocifensive behaviour.
Animal model of P-CTX-1-evoked visceral pain. To assess the contribution of NaV isoforms to the 
gastrointestinal symptoms associated with ciguatera, we established a novel model of P-CTX-1-induced visceral 
hypersensitivity. Male C57BL/6 mice house on AlphaDri bedding were fasted overnight with ad-libitum access to 
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water. P-CTX-1 (10 nM, 50 μ l) in sterile saline was administered under light isoflurane (3%) anaesthesia via a soft, 
flexible, round-tipped catheter that was advanced 3 cm from the anus. The NaV1.8 blocker A-803467 (100 mg/kg) 
was diluted in PEG400 and administered in a volume of 2 μ l/g by intraperitoneal injection as previously described62. 
To avoid systemic adverse effects TTX (100 nM) was co-administered by intra-colonic administration with 
P-CTX-1. Animals were allowed to recover for 15 min and then placed into the recording chamber of a Behavioral 
Spectrometer (Behavioral Instruments, Hillsborough, NJ, USA) for automatic detection of still, grooming, orient-
ing, rearing and locomotion behaviours as previously described by combining video and vibration analysis64.
Phosphorylated MAP kinase ERK 1/2 (pERK) quantification in spinal cord. Mice were anaesthe-
tised in an isofluorane chamber and received an enema of either vehicle (0.3% bovine serum albumin in 0.1 M 
phosphate buffer saline) or P-CTX-1 (1 nM in 0.3% bovine serum albumin in 0.1 M phosphate buffer saline). After 
5 minutes mice were injected with an anaesthetic overdose (0.125 ml/250 g sodium pentobarbitone) and within 
4 min underwent transcardial perfuse fixation with warm saline (0.85% physiological sterile saline) followed by 
ice-cold 4% paraformaldehyde in 0.1 M phosphate buffer (Sigma-Aldrich, MO, USA). Following transcardial 
perfusion thoracolumbar (T10-L1) spinal cord was removed, using the lowest rib as an anatomical marker of 
T13, and post-fixed for 16 hours at 4 °C in 4% paraformaldehyde in 0.1 M phosphate buffer. Following fixation 
spinal cord were cryoprotected in 30% sucrose/phosphate buffer (Sigma-Aldrich, MO, USA) overnight at 4 °C 
and then placed in 50% Optimal Cutting Temperature compound (OCT; Tissue-Tek, Sakura Finetek, CA, USA) 
in 30% sucrose/phosphate buffer solution for 7 h, before block freezing in 100% OCT. Frozen sections (15 μ m) 
were cut using a cryostat and placed onto saline coated slides for fluorescent immunohistochemistry.
Immunohistochemistry for pERK was performed in a paired fashion, with tissue from saline or P-CTX-1 treated 
mice run simultaneously. Following 20 min of air drying, sections were flushed 3 times with PBS and incubated with 
5% normal chicken serum/0.2% Triton-X 200 (Sigma-Aldrich, MO, USA) in PBS (0.2% TX-PBS) for 30 min at 
room temperature to block non-specific binding of secondary antibodies. Sections were then incubated for 18 h 
at room temperature with monoclonal anti-sera rabbit anti-phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) 
(pERK; 1:200; Cell Signalling Technology #4370) diluted in 0.2% TX-PBS. Sections were then washed 3 times with 
0.2% TX-PBS before being incubated for 1 h at room temperature with secondary antibody chicken anti-rabbit 
AlexaFluorR488 (AF-488). Negative controls were prepared as above with the primary antibody omitted.
NaV isoform expression studies using Quantitative-Reverse-Transcription-Polymerase- 
Chain-Reaction (QRT-PCR). Whole DRG QRT-PCR. RNA was extracted isolated using the PureLink 
RNA Micro kit (Invitrogen, cat #12183-016) and DNAse treated (LifeTechnologies cat #12185-010) following 
the manufacturer’s instruction. RNA was stored at − 80 °C in aliquots of 1–3 μ l. QRT-PCR was performed using 
EXPRESS One-Step Superscript® qRT-PCR Kit (Life Technologies cat #11781-01 K) with commercially available 
hydrolysis probes (TaqMan® ; LifeTechnologies, see Table 3 for details) and DEPC-treated water (AMBION cat 
#AM9916). For each reaction, 10 μ l qPCR SuperMix, 1 μ l TaqMan® primer assay, 0.04 μ l ROX, 2 μ l water, 2 μ l 
SuperScript Reverse Transcriptase and 5 μ l RNA (45 ng/well, except human colon biopsies at 30 ng/well) was used 
in all experiments. Beta-actin was used as reference gene. PCR runs were performed in duplicate for each sample 
on a 7500 Fast machine (Applied Biosystems).
Single Cell PCR of colonic DRG neurons. AlexaFluor488 conjugated cholera-toxin subunit β retrograde traced single 
cells were picked using a micromanipulator under an Olympus microscope equipped with appropriate fluorescent fil-
ter. Cells were under a continuous flow of sterile and RNA/DNAse free PBS in order to reduce contamination. After a 
cell was picked, the glass capillary was broken into a tube containing 10 μ l of lysis buffer and DNAse (TaqMan® Gene 
Expression Cells-to-CT™ Kit). For every coverslip a bath control was analysed together with other samples. Tubb3 
expression served as positive control, with GFAP expression measured to exclude contamination with glial cells.
Statistical analysis. Data are represented as mean ± SEM. Statistical significance was defined as p < 0.05 
and was determined using paired or unpaired student’s t-tests and One-way ANOVA analysis with post-tests as 
indicated. Statistical analysis was performed using GraphPad Prism Version 6.00.
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